Abstracts, Posters, Presentations and Publications.
iLSTA Trial Update – ASCO
Promising early results from one of WARPNINE’s most important clinical trials.
This report shares the first patient outcomes from the iLSTA trial, which is testing a new combination of chemotherapy, immunotherapy, and a targeted delivery agent for pancreatic cancer. Some patients have shown significant tumour shrinkage and signs of immune system engagement.
​
Read the update presented at a leading international cancer conference.
Microbiome and Treatment Response – ASCO Abstract
Could gut bacteria influence how patients respond to cancer treatment?
This research explores how the bacteria in our digestive system may play a role in how well people with pancreatic cancer respond to treatment. It’s one of the first studies of its kind and was presented at a major international oncology conference.
​
Microbiome Changes During Treatment –
ASCO Abstract
What happens to the microbiome during cancer treatment?
This study followed patients through treatment to see how their gut bacteria changed—and found signs that combining chemotherapy and immunotherapy might improve microbial balance in ways that could support better outcomes.
Tumour-Infiltrating Lymphocytes (TILs) – ASCO Abstract
How do we know if the immune system is responding to treatment?
This research shows that the iLSTA trial didn’t just shrink tumours—it also triggered a response from the body’s immune cells. That’s a key sign the treatment is doing more than just attacking the cancer.
​
iLSTA -
Abstract Submission
A closer look at the science behind the iLSTA trial.
This summary explains the structure of the iLSTA trial, what’s being tested, and why it matters. It outlines how the trial was designed and highlights early results that helped build international interest in this new approach.
Microbiome Changes During Treatment –
Abstract Submission
Tracking the microbiome over time.
This version of the microbiome study focuses on how gut bacteria shifted during treatment and what those changes could mean for future therapies.
Microbiome and Treatment Response – Abstract Submission
The relationship between gut health and cancer care.
This abstract explains how differences in gut bacteria may help predict who responds well to treatment—and who might need a different approach.
Posters
ASCO Poster –
iLSTA Trial in Progress
Presented at the 2024 ASCO Gastrointestinal Cancers Symposium.
This poster outlines early findings from WARPNINE’s iLSTA trial, exploring a new approach to treating pancreatic cancer using immunotherapy and enhanced drug delivery. The data shows encouraging tumour response and immune activation in patients who previously had limited options.​
​
ASCO Poster – Microbiome & Treatment Response
How gut health might influence cancer treatment.
This poster presents groundbreaking research from the iLSTA trial linking gut bacteria to how well patients respond to chemotherapy and immunotherapy. Shared at ASCO GI 2024, it suggests that the microbiome could play a powerful role in future treatment planning.
​
AGITG ASM 2024 Poster – iLSTA Trial in Progress
Updated results from our flagship pancreatic cancer trial.
Presented at AGITG ASM 2024, this poster shares updated insights from the iLSTA trial, including tumour response, immune activity, and safety outcomes. It highlights the potential of combining immunotherapy with precision delivery agents in pancreatic cancer.
​
AGITG ASM 2024 Poster – Microbiome & Cancer Response
Could gut bacteria help predict how patients respond to treatment?
This poster, shared at AGITG ASM 2024, dives deeper into how changes in the microbiome during treatment may be linked to outcomes in pancreatic cancer. The findings support further research into how we can personalise care using microbiome data.
​
Publications
The Lancet
Gastroenterology & Hepatology​
​
Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study​
​
Published: July 05, 2022 DOI: https://doi.org/10.1016/S2468-1253(22)00167-4
We are delighted to share the findings, recently published in The Lancet, from the first-in-human study by Dr Andrew Dean, Chair of WARPNINE, and colleagues.
​
Although early phase, this study showed the best ever result ever seen in a pancreatic cancer trial.
This article was published in The Lancet Gastroenterology & Hepatology, Vol 7, Andrew Dean, Sanjeev Gill, Mark McGregor, Vy Broadbridge, Harri A Järveläinen, Timothy Price, Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study, Copyright Elsevier Ltd (2022).